Company / Revenue
Gain Therapeutics, Inc. Revenue History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$55.2K
FY2024
5-year range
$28.9K / $165.0K
FY2021-FY2024
Trend
-60.6%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $164,994 to $55,180 over the past 2 years.
Based on SEC 10-K filings.
$55,180 in FY2024 with a 3-year CAGR of +24.1%.
Declined from $164,994 to $55,180 over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- +24.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +24.1%, indicating consistent growth.
- In FY2024, revenue decreased 60.6% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $55.2K | -60.6% |
| FY2023 | $140.1K | -15.1% |
| FY2022 | $165.0K | +471.3% |
| FY2021 | $28.9K | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026